In an adult patient with normal renal and hepatic function, which antibiotic provides coverage for both methicillin‑resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa?

No Single Antibiotic Covers Both MRSA and Pseudomonas

You must use combination therapy—there is no single antibiotic that adequately covers both MRSA and Pseudomonas aeruginosa. The standard approach requires pairing an anti-MRSA agent (vancomycin or linezolid) with an antipseudomonal beta-lactam (such as cefepime, piperacillin-tazobactam, or meropenem) 1.

The Combination Therapy Approach

According to the 2016 IDSA/ATS guidelines for hospital-acquired pneumonia, when dual coverage is needed:

For MRSA Coverage:

• Vancomycin 15 mg/kg IV q8-12h (target trough 15-20 mg/mL)
• OR Linezolid 600 mg IV q12h

For Pseudomonas Coverage:

• Piperacillin-tazobactam 4.5 g IV q6h
• OR Cefepime 2 g IV q8h
• OR Ceftazidime 2 g IV q8h
• OR Meropenem 1 g IV q8h
• OR Imipenem 500 mg IV q6h

The guidelines explicitly state to avoid using two beta-lactams together 1.

Why Single-Agent Coverage Fails

Fluoroquinolones Have Limitations:

While newer fluoroquinolones like delafloxacin show in vitro activity against both MRSA and Pseudomonas 2, and ciprofloxacin/levofloxacin appear in the HAP guidelines 1, they are:

• Not recommended as monotherapy for serious MRSA infections
• Associated with rapid resistance development
• Less reliable than vancomycin/linezolid for MRSA

Ceftobiprole Shows Poor Pseudomonas Activity:

Research demonstrates that while ceftobiprole has excellent MRSA activity (100% susceptibility), it performs poorly against multidrug-resistant Pseudomonas with only 30.2% susceptibility 3. This makes it unsuitable as a dual-coverage agent.

Clinical Decision Algorithm

When to use dual MRSA + Pseudomonas coverage:

1. High risk of mortality (ventilatory support, septic shock)
2. Prior IV antibiotics within 90 days
3. MRSA prevalence >20% in your unit
4. Structural lung disease (bronchiectasis, cystic fibrosis)
5. Recent hospitalization or healthcare exposure

Dosing considerations:

• Extended infusions of beta-lactams may be appropriate for Pseudomonas
• Vancomycin requires therapeutic drug monitoring
• Consider loading dose of vancomycin (25-30 mg/kg × 1) for severe illness 1

Critical Pitfalls to Avoid

• Never rely on a single agent when both pathogens are suspected—the microbiologic failure rate is unacceptably high
• Don't use two beta-lactams together—they compete for the same bacterial cell wall targets and provide no additional benefit 1
• Don't delay appropriate coverage—early appropriate therapy significantly impacts mortality in severe infections
• Always check local antibiograms—resistance patterns vary by institution and should guide empiric choices 1

The evidence consistently shows that serious infections requiring coverage of both organisms demand combination therapy tailored to local resistance patterns and patient-specific risk factors.